

BIOSTOCK PUBLISHES ARTICLE ABOUT PROLIGHT DIAGNOSTICS Q4 REPORT

Prolight Diagnostics' year-end report for 2023 shows that the company met all the goals for the year. The company's point-of-care analysis system has shown proof-of-performance for measurement of troponin in whole blood. In addition, the company has formed a Clinical Advisory Board and established an R&D manufacturing line for the upcoming pilot production. The goal for 2024 is to complete the development of the system for clinical validation.

Read the full article at: <https://www.biostock.se/en/2024/02/prolight-diagnostics-ceo-we-deliver-on-all-goals/>

For further information, please contact:

Prolight Diagnostics AB (publ)

E-mail: info@prolightdx.com

Telephone: +46 73 582 39 87

Website: www.prolightdx.com/en/

About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

[Biostock publishes article about Prolight Diagnostics Q4 report](#)